Pain is highly prevalent in patients with cancer—nearly 40% report moderate-severe pain,
which is commonly treated with opioids. Increasing cancer survivorship, opioid epidemics in …

Background Collection of Patient Reported Outcome (PRO) data can facilitate cost-effective,
evidence-based, and patient centered care. The BREAST-Q has become the gold standard …

Background: Given that peripheral arterial disease (PAD) disproportionately affects people
of lower socioeconomic status, out-of-pocket expenses for preventive medications are a …

Introduction Daily medication is the cornerstone of evidence-based therapy to reduce mortality
and morbidity in patients with heart failure (HF). Up to 20% of Canadian patients pay for …

Objectives: Given problems with, and limitations of, opioid use for cancer-related pain, the
identification of nonopioid treatment strategies that could improve cancer pain care is an …

Purpose Cancer treatment is a significant driver of healthcare costs worldwide, however, the
economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We …

810 Background: Cancer treatment is a significant driver of healthcare costs worldwide,
however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated…

Methods: Ethics approval was not applicable because this study did not involve human or
animal research. The protocol for this review has been previously published and registered in …

Purpose: Idiopathic focal segmental glomerulosclerosis (FSGS) and minimal change disease
(MCD) are chronic glomerulopathies which may compromise patients’ quality of life, and …

Background: Collection of patient-reported outcome (PRO) data can facilitate cost-effective,
evidence-based, and patient-centered care. The BREAST-Q has become the gold standard …